NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
